Regional meeting to scale up collaborative TB/HIV activities begins in Maputo

"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports. "Provision of early antiretroviral treatment to individuals co-infected with HIV and TB was the focus of the session," the blog notes, adding, "Later in the morning, a Tanzania Ministry of Health official discussed her country's effort to meet the challenge of TB/HIV co-infection in a nation of 44 million people where HIV prevalence is a little more than five percent, and 38 percent of TB patients live with HIV" (Lubinski, 4/15).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug